Davenport & Co’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.09M Buy
24,476
+258
+1% +$34K 0.02% 476
2026
Q1
$3.38M Sell
24,218
-15,986
-40% -$2.24M 0.02% 416
2025
Q4
$4.93M Buy
40,204
+2,643
+7% +$321K 0.03% 344
2025
Q3
$4.17M Sell
37,561
-6,026
-14% -$685K 0.02% 370
2025
Q2
$4.83M Sell
43,587
-16,332
-27% -$1.74M 0.03% 328
2025
Q1
$6.71M Sell
59,919
-11,178
-16% -$1.15M 0.04% 267
2024
Q4
$6.57M Sell
71,097
-2,482
-3% -$223K 0.04% 266
2024
Q3
$6.17M Buy
73,579
+4,378
+6% +$334K 0.04% 269
2024
Q2
$4.75M Buy
69,201
+6,820
+11% +$455K 0.03% 305
2024
Q1
$4.57M Buy
62,381
+14,475
+30% +$1.11M 0.03% 313
2023
Q4
$3.88M Sell
47,906
-2,088
-4% -$162K 0.03% 308
2023
Q3
$3.75M Sell
49,994
-1,484
-3% -$114K 0.03% 293
2023
Q2
$3.97M Sell
51,478
-8,763
-15% -$699K 0.03% 290
2023
Q1
$5M Sell
60,241
-27,747
-32% -$2.3M 0.04% 267
2022
Q4
$7.55M Sell
87,988
-12,105
-12% -$959K 0.06% 196
2022
Q3
$6.17M Buy
100,093
+6,090
+6% +$384K 0.05% 213
2022
Q2
$5.81M Buy
94,003
+11,845
+14% +$733K 0.05% 224
2022
Q1
$4.88M Buy
82,158
+14,114
+21% +$902K 0.03% 269
2021
Q4
$4.94M Sell
68,044
-3,675
-5% -$253K 0.03% 265
2021
Q3
$5.01M Buy
71,719
+15,234
+27% +$1.07M 0.04% 249
2021
Q2
$3.89M Buy
56,485
+37,002
+190% +$2.47M 0.03% 241
2021
Q1
$1.26M Buy
19,483
+885
+5% +$57.1K 0.01% 348
2020
Q4
$1.08M Buy
18,598
+2,632
+16% +$159K 0.01% 355
2020
Q3
$1.01M Buy
15,966
+544
+4% +$37.7K 0.01% 339
2020
Q2
$1.19M Buy
15,422
+5,188
+51% +$398K 0.01% 303
2020
Q1
$765K Sell
10,234
-576
-5% -$39.8K 0.01% 337
2019
Q4
$702K Buy
10,810
+4,760
+79% +$310K 0.01% 402
2019
Q3
$409K Sell
6,050
-515
-8% -$33.7K ﹤0.01% 497
2019
Q2
$444K Buy
6,565
+299
+5% +$19.7K 0.01% 473
2019
Q1
$407K Buy
6,266
+202
+3% +$13.4K 0.01% 465
2018
Q4
$379K Sell
6,064
-64
-1% -$4.47K 0.01% 461
2018
Q3
$473K Sell
6,128
-719
-11% -$54.3K 0.01% 453
2018
Q2
$485K Sell
6,847
-3,420
-33% -$242K 0.01% 446
2018
Q1
$774K Sell
10,267
-3,347
-25% -$266K 0.01% 358
2017
Q4
$975K Sell
13,614
-470,454
-97% -$35.7M 0.01% 322
2017
Q3
$39.2M Buy
484,068
+6,711
+1% +$513K 0.5% 86
2017
Q2
$33.8M Buy
477,357
+346,114
+264% +$23M 0.45% 95
2017
Q1
$8.97M Buy
131,243
+115,295
+723% +$8.11M 0.13% 120
2016
Q4
$1.14M Buy
15,948
+4,013
+34% +$298K 0.02% 271
2016
Q3
$944K Sell
11,935
-4,850
-29% -$394K 0.01% 297
2016
Q2
$1.4M Buy
16,785
+734
+5% +$65.1K 0.02% 242
2016
Q1
$1.47M Sell
16,051
-1,586
-9% -$143K 0.02% 228
2015
Q4
$1.78M Sell
17,637
-1,042
-6% -$108K 0.03% 209
2015
Q3
$1.83M Buy
18,679
+7,682
+70% +$853K 0.03% 212
2015
Q2
$1.29M Buy
10,997
+1,128
+11% +$123K 0.02% 256
2015
Q1
$968K Sell
9,869
-26,310
-73% -$2.67M 0.01% 305
2014
Q4
$3.41M Buy
36,179
+1,668
+5% +$173K 0.06% 174
2014
Q3
$3.67M Buy
34,511
+2,231
+7% +$218K 0.06% 159
2014
Q2
$2.68M Buy
32,280
+1,366
+4% +$106K 0.05% 186
2014
Q1
$2.19M Buy
30,914
+5,222
+20% +$410K 0.04% 196
2013
Q4
$1.93M Buy
25,692
+11,063
+76% +$770K 0.04% 193
2013
Q3
$920K Buy
+14,629
New +$874K 0.02% 259

Other funds holding GILD

Davenport & Co's GILD Position: Q2 2026 in Review

Davenport & Co increased its Gilead Sciences (GILD) stake by 1.1% in Q2 2026, buying an estimated $34K and bringing the position to 24,476 shares worth $3.09M. The position accounts for 0.02% of the portfolio, ranked #476.

Davenport & Co first reported a position in GILD in Q3 2013 and has held it in 52 quarters since. The position peaked at $39.2M in Q3 2017. 512 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Davenport & Co held 24,476 shares of Gilead Sciences worth $3.09M as of Q2 2026.
  • Davenport & Co bought 258 Gilead Sciences shares in Q2 2026, an estimated $34K.
  • Gilead Sciences made up 0.02% of Davenport & Co's portfolio in Q2 2026, its #476 holding.
  • Davenport & Co first reported a position in Gilead Sciences in Q3 2013 and has held it in 52 quarters since.
  • Davenport & Co's Gilead Sciences position peaked at $39.2M in Q3 2017.
  • 512 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.